Structure (Fe06b979 134e 4ba2 9f86 Ab442a3562a1 01)
Mirabegron Tablet, Extended Release
Product Images NDC 70710-1160
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Mirabegron (NDC 70710-1160). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Zydus Pharmaceuticals (usa) Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Fe06b979 134e 4ba2 9f86 Ab442a3562a1 02)
Figure 2 (Fe06b979 134e 4ba2 9f86 Ab442a3562a1 03)
Figure 3 (Fe06b979 134e 4ba2 9f86 Ab442a3562a1 04)
Figure 4 (Fe06b979 134e 4ba2 9f86 Ab442a3562a1 05)
Figure 5 (Fe06b979 134e 4ba2 9f86 Ab442a3562a1 06)
Figure 6 (Fe06b979 134e 4ba2 9f86 Ab442a3562a1 07)
Mean Change from Baseline:
- Placebo group (n=433)
- Week
- Mirabegron 50 mg group (n=425)*
Figure 7 (Fe06b979 134e 4ba2 9f86 Ab442a3562a1 08)
This text appears to be a table showing the mean change from baseline for a certain variable. The values range from 0.00 to -2.00, with increments of -0.25. The table also includes a value of =175, which could be a reference to a specific calculation or result. Additionally, there are mentions of "mirabegron" in different dosages (25 mg and 50 mg), along with corresponding sample sizes (n=254 and n=257). The rest of the text is either unclear or irrelevant.*
Figure 8 (Fe06b979 134e 4ba2 9f86 Ab442a3562a1 09)
Mirabegron Extended-release Tablets, 25mg (Fe06b979 134e 4ba2 9f86 Ab442a3562a1 10)
Mirabegron Extended-release Tablets, 50mg (Fe06b979 134e 4ba2 9f86 Ab442a3562a1 11)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
